# **Product** Data Sheet

## RMC-4550

**Cat. No.:** HY-116009

Molecular Weight: 437.36

Target: Phosphatase; SHP2

Pathway: Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK

Storage: Powder -20°C 3 years

Powder -20°C 3 years 4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (228.64 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.2864 mL	11.4322 mL	22.8645 mL
	5 mM	0.4573 mL	2.2864 mL	4.5729 mL
	10 mM	0.2286 mL	1.1432 mL	2.2864 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.72 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.72 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.72 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

**Description** RMC-4550 is a potent, selective and allosteric inhibitor of SHP2, with an IC<sub>50</sub> of 0.583 nM.

IC50:0.583 nM (SHP2)<sup>[1]</sup>.

In Vitro

RMC-4550 is an allosteric inhibitor of SHP2 and stabilizes the auto-inhibited conformation of wild-type SHP2 enzyme, with a mode of inhibition similar to SHP099. Consistent with an allosteric mode of inhibition, RMC-4550 inhibits the activity of full-length wild-type SHP2 enzyme activated by a di-phosphotyrosine peptide, but lacks activity against the free catalytic

#### domain of $SHP2^{[1]}$ .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **CUSTOMER VALIDATION**

- Cancer Discov. 2021 Jul;11(7):1716-1735.
- Cancer Res. February 09 2022.
- Cancer Res. 2020 Aug 15;80(16):3413-3423.

See more customer validations on  $\underline{www.MedChemExpress.com}$ 

#### **REFERENCES**

[1]. Nichols RJ, et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat Cell Biol. 2018 Sep;20(9):1064-1073.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: tech@MedChemExpress.com}$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA